

## HM2023-07: Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

1. diagnosed with multiple myeloma that has not responded to treatment or has reoccurred after at least one treatment 2. able to care for self with some assistance

#### Exclusion Criteria:

1. active cancer in central nervous system or clinical symptoms 2. maximum amount of steroids taken in the past two weeks (study staff will review) 3. disease hasn't responded to this type of drug (anti-CD38 monoclonal antibody)

### Conditions & Interventions

#### Interventions:

Drug: Daratumumab, Drug: Dexamethasone, Drug: Pomalidomide, Drug: Talquetamab

#### Conditions:

Cancer

#### Keywords:

Multiple Myeloma

### More Information

**Description:** Talquetamab is an experimental medication being studied to see if it may be beneficial in the treatment of multiple myeloma.

**Study Contact:** Daniel O'Leary - dholeary@umn.edu

**Principal Investigator:** Daniel O'Leary

#### IRB

**Number:** STUDY00018679

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.